Article

Design of Mucoadhesive Strips for Buccal Fast Release of Tramadol

Nayla Francine Garcia Pastório, Camila Felix Vecchi, Rafaela Said dos Santos and Marcos Luciano Bruschi *

Laboratory of Research and Development of Drug Delivery Systems, Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, State University of Maringa, Maringa, PR 87020-900, Brazil; naylafrangarcia@gmail.com (N.F.G.P.); camilaf.vecchi@gmail.com (C.F.V.); rafaelasaid@gmail.com (R.S.d.S.) * Correspondence: mlbruschi@uem.br; Tel.: +55-44-30115998; Fax: +55-44-3011-4999

Abstract: Tramadol hydrochloride is a synthetic analogue of codeine and shows activity on the central nervous system as an opioid agonist and inhibitor of serotonin and norepinephrine reuptake. It has been used for controlling moderate to severe pain. Mucoadhesive fast-dissolving films can present greater drug availability and patient acceptance when compared to the systems of peroral administration. The films were prepared using the solvent casting method with ethylcellulose, polyvinylpyrrolidone and poly(vinyl alcohol). The effect of each polymer concentration was investigated using a 2³ factorial design with repetition at the central point. The formulations were subjected to physicochemical, mechanical, ex vivo mucoadhesive and in vitro drug release profile analysis. These properties were dependent on the polymeric composition (independent factors) of each system. The optimized formulations showed good macroscopic characteristics, improved resistance to bending, rigidity, rapid swelling up to 60 s, improved mechanical and mucoadhesive characteristics, and also fast dissolving and tramadol release. The optimized formulations constitute platforms and strategies to improve the therapy of tramadol with regard to availability at the site of application, considering the necessity of rapid pain relief, and show potential for in vivo evaluation.

Keywords: thin films; mucoadhesion; fast dissolving; development; mechanical properties; polymeric systems

1. Introduction

Pain may be defined as an unpleasant sensory and emotional experience accompanied with actual or potential tissue damage [1,2]. The single and most reliable pain indicator is the self-report of the patient. Biological, psychological, and social factors can influence this personal experience to varying degrees [2]. Individuals learn about the concept of pain through their life experiences. Thus, pain plays an adaptive role, which may have adverse effects on well-being and psychological and social function [3,4]. This uncomfortable feeling may be classified into acute or chronic [2,3,5] and emotional or sensory pain [4]. Recommendable appropriate analgesics for emotional pain are anxiolytics (minor tranquilizers), antidepressants, and antipsychotics (major tranquilizers). However, for sensory pain, the recommendations are different. Anticonvulsivants and antidepressants are recommended for neuropathic pain, while non-steroidal anti-inflammatory drugs (NSAIDs), n-acetyl-para-aminophenol, acetyl salicylic acid, steroids and opioids are indicated for nociceptive pains, such as somatic and visceral pain [4].

Tramadol is a synthetic 4-phenyl-piperidine analogue of the opioid drug codeine that acts on the central nervous system as an agonist, by inhibition of serotonin and norepinephrine reuptake, while its metabolite o-desmethyltramadol acts on the μ-opioid receptor [6–8]. The chemical formula of tramadol is 2-(dimethyl amino)-methyl)-1-(3-methoxyphenyl) cyclohexanoylhydrochloride, and it was first synthesized in 1962 by the west German pharmaceutical company Grünenthal GmbH (Stolberg, Germany), introduced to the
market under the trade name Tramal® in 1977. Its potency is about one-tenth that of morphine, but is preferred due to it being safer than the latter [7,8].

The discovery of tramadol revolutionized the pain medication market. This active pharmaceutical ingredient (API) is utilized for the treatment of both acute and chronic pain of moderate to severe intensity. Compared with other opioid analgesics, it does not cause respiratory depression and addiction [6,7]. Tramadol displays different characteristics from opioids available on the market, namely its dual action mechanism, which allows it to maintain a large part of its effectiveness. It exhibits agonistic activity to the µ-opioid receptor (MOR) and the central GABA catecholamine and serotonergic receptors [7]. Therefore, it is mainly utilized in the management of chronic pain and as first-line API in the treatment of joint, muscle and wound pain, including the therapy of postoperative or orthopedic injury induced acute pain [6,7,9].

Formulations containing tramadol are available for peroral administration (tablet, capsule and syrup), parenteral administration (intramuscular and intravenous), and local administration (cream, gel and ointment) [6–8]. It is an API of high solubility and permeability (biopharmaceutical classification-I) [6,7,10]. This characteristic enables the dissolved drug molecules of tramadol to permeate through the mucosal membrane and to reach the microvasculature. Therefore, the API is rapidly absorbed and has a half-life of approximately three hours, often requiring a larger number of doses to promote the proposed therapeutic effect [6–10]. For the effective management of the therapeutic condition, in the case of patients with orthopedic problems, presenting problems in the musculoskeletal system, ligaments and joints, it is very common to administer several doses of tramadol in order to maintain an adequate and constant concentration for a certain period of time [9]. For example, when administered orally, tramadol is utilized at 50–100 mg every 4–6 h with or without food. The maximum dose of this API is 400 mg/day, and it is intravenously and intramuscularly used in severe pain with a dose of 50–100 mg every 4–6 h [6–8].

Considering the degree of invasiveness of the parental route of administration, as well as the need for frequent doses through oral administration, patient compliance with treatment and therapy may be impaired. In addition, the fast effect/action of tramadol against pain is necessary in cases of acute pain. Therefore, it is necessary to optimize the administration route and the development of platforms for the modified and/or controlled release of tramadol in order to overcome these inconveniences.

Transmucosal route of drug delivery can offer important advantages over the other administration routes for systemic delivery, including the possible bypass of the first-pass effect and avoidance of presystemic elimination within the gastrointestinal tract [11,12]. The mouth is an accessible site for the administration of pharmaceutical systems, and the buccal drug administration is widely accepted for potent medicines for the clinical situations associated with discomfort and severe pain [9,11,12].

Mucoadhesive systems can provide intimate contact between a pharmaceutical system and the absorbing tissue, which can result in a high drug concentration in a local area and high drug flux through the absorbing tissue [11–13]. Different dosage forms showing mucoadhesive properties intended for buccal administration have been proposed, such as tablets, patches and adhesive semisolid systems [11,14,15]. These systems must keep intimate contact with the mucosal membrane, facilitating both mucus interaction and permeation and epithelial absorption as well [12]. Patches can be designed to constitute simple erodible and no erodible mucoadhesive films and to provide either unidirectional or multidirectional drug release [11]. These systems can be developed for prolonged or for rapid release.

Fast-dissolving films or strips have gained acceptance and popularity due to their rapid disintegration/dissolution, and as they can be self-administered even without water or chewing. They can also overcome difficulties of administration associated with solid dosage forms for geriatric and pediatric patients [15,16].
Mucoadhesive buccal systems containing tramadol have been proposed. Despite them having displayed a prolonged release, the rapid effect of the drug has shown to be impaired [9,17]. In previous studies, we have developed mucoadhesive films comprising polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), and poloxamer 407 for pharmaceutical applications [18]. They showed good mucoadhesive properties and improved performances for fast drug delivery [19,20]. Therefore, the objective of this work was to develop a mucoadhesive polymeric platform in the form of a fast-dissolving strip composed of PVA, PVP, and ethylcellulose for buccal delivery of tramadol. These polymers are already used in the composition of many pharmaceutical dosage forms and exhibit good performances, safeness and cytocompatibility [18–20]. Design, technological preparation, physicochemical and mechanical characterization, in vitro drug release, and mucoadhesiveness evaluations of the system were performed.

2. Materials and Methods

2.1. Materials

Tramadol hydrochloride was purchased from Cadila Healthcare Limited (Gujarat, India) and ethylcellulose (EC; Surelease® grade E–7-19040) was from Colorcon (Cotia, SP, Brazil). Polyvinylpyrrolidone (PVP, mm = 111.14 g/mol) was purchased from Labsynth (Sao Paulo, SP, Brazil) and poly(vinyl alcohol) (PVA, mm = 44.05 g/mol) was received from Neon (Sao Paulo, SP, Brazil). Absolute ethanol was received from Vetec® (Duque de Caxias, RJ, Brazil) and methanol (analytical grade) was purchased from Merck (Sao Paulo, SP, Brazil). Ultra-purified water utilized in all experiments was obtained from an Evoqua® apparatus (Günzburg, Germany).

2.2. Design and Preparation of Systems

A full factorial design $2^3$ was employed to investigate the influence of PVA ($X_1$), PVP ($X_2$), and EC ($X_3$) concentrations that have a significant influence on the study response. The independent variables (PVP, PVA, or EC) were evaluated at two levels, low (−) or high (+), as displayed in Table 1. Moreover, two central points (F9 and F10) were also evaluated for detection of curvature and errors associated with isolated effects or the interactions among them, totaling ten formulations.

**Table 1.** Matrix of factorial design matrix $2^3$ (plus two center points) for formulations containing polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), ethylcellulose (EC) and tramadol (10%, w/w) *.

| Independent Variables/Factors (%, w/w) ** | Low ($-1$) | Central (0) | High ($+1$) |
|------------------------------------------|------------|-------------|-------------|
| $X_1$ = PVA                             | 50         | 60          | 70          |
| $X_2$ = PVP                             | 10         | 20          | 30          |
| $X_3$ = EC                              | 12.5       | 15          | 17.5        |
| Standard run (formulations)             |            |             |             |
| F1                                      | -          | -           | -           |
| F2                                      | -          | -           | +           |
| F3                                      | +          | -           | -           |
| F4                                      | +          | -           | +           |
| F5                                      | -          | +           | -           |
| F6                                      | -          | +           | +           |
| F7                                      | +          | +           | -           |
| F8                                      | +          | +           | +           |
| F9 (C)                                  | 0          | 0           | 0           |
| F10 (C)                                 | 0          | 0           | 0           |

* The dryness film; ** the liquid dispersion; C = center point.
They were prepared by dispersing the polymers and drug in a suitable solvent (purified water or absolute ethanol). PVA was dissolved in purified hot water at 70 °C and PVP was dissolved in ethanol under magnetic stirring. EC and the drug were also dispersed separately in purified water. A suitable amount of tramadol hydrochloride with 10% (w/w) of drug in each formulation was dissolved in purified water, at room temperature, and under magnetic stirring until complete dissolution. This aqueous solution of tramadol hydrochloride was added to the PVA solution (at 25 °C), under stirring for 5 min. Afterwards, the EC and PVP solutions were also added under agitation for the time required until complete homogenization. The final dispersion was poured into circular plates for drying in a circulating air oven at 50 °C for 4 h. Afterwards, the films were removed from the molds and macroscopically evaluated for integrity, homogeneity, flexibility, presence of air bubbles, color and touch adhesion [18]. They were kept dry, at room temperature, and protected from light until the further analyses.

2.3. Analysis of Thickness and Density

The film samples were measured as thickness at five random sites using a micrometer. Three samples from each formulation, measuring 1 cm², were oven-dried at 40 °C for 20 h, and weighed using analytical balance. Afterwards, the density of each film sample was determined according to the following equation [18,21–23]:

\[
D = \frac{m}{A \cdot h}
\]

(1)

where \(D\) is the density (g/mL), \(m\) is the mass (g), \(A\) is the surface area (mm²), and \(h\) is the thickness (mm) of film sample. At least three replicates were carried out to estimate the inherent variability of each analysis.

2.4. Determination of the Swelling Index

The analysis of moisture uptake capacity of formulations was determined using samples of 100 mm² area. The strips were dried using a fan-assisted oven, at temperature of 40 °C up to constant weight. Afterwards, each sample was weighed and immediately submerged in purified water. After 60 s, the excess water was gentle removed using an absorbent paper, and the film sample was weighed again. The following equation was utilized to determine the swelling index (SI) [22]:

\[
SI (\%) = \left( \frac{W_s - W_d}{W_d} \right) \cdot 100
\]

(2)

where \(W_s\) is the swelled strip weight and \(W_d\) is the dried strip weight. The analyses were carried out at least in triplicate to estimate the inherent variability of each determination.

2.5. Mechanical Evaluation

2.5.1. Folding Endurance

The bending strength of film formulations was evaluated by repeatedly folding the samples over the same place to break or reaching 300 folds. The number of times the sample could be folded without rupture indicated the value of bending strength [21,24]. At least three replicates of each film formulation were evaluated.

2.5.2. Tensile Analysis

The mechanical characteristics of film formulations were evaluated using a TA-XTplus texture analyzer (Stable Micro Systems, Surrey, England) in tension mode. The resistance to applied tension, Young’s modulus, force required for breaking, and elongation (maximum distance traveled until braking of the sample) of samples were determined [18,25]. Briefly, the samples were cut 50 mm in length and 10 mm in width, with 15 mm of each end of the sample in contact with the base (plate) of the apparatus, so that
20 mm was exposed. One of the tensile grips (ranging 35 × 35 mm) was fixed to the stationary base and the other to the travelling arm that moved at a speed of 2 mm/s up to the sample rupture. Young’s modulus, the forces of maximum tension (Tmax) and of fracture (F) at breakpoint were determined. The analyses were carried out at least in three replicate samples to estimate the inherent variability of each determination.

2.6. Ex Vivo Evaluation of Mucoadhesive Properties

The analysis of mucoadhesive properties of film formulations was accomplished using a TA-XTplus texture analyzer (Stable Micro Systems, Surrey, UK) in tension mode [26]. The mucoadhesive force of each sample was evaluated using the force required to remove the porcine buccal mucosa from the formulation. The mucosal tissue was obtained from pigs (white, young, and recent sacrificed) originated from a local slaughterhouse (authorized by the Brazilian Ministry of Agriculture for human consumption). Porcine buccal mucosa samples were cleaned with phosphate saline buffer (PSB) and prepared with an area of 132.73 mm², using a surgical scalpel, whilst taking care to avoid the use of samples displaying wounds or bruises. The mucosal tissue was then horizontally attached to the lower termination of the probe (cylindrical, P/6), using double sided adhesive tape. A film sample was placed on a support at the bottom, and a downward force (0.03 N) was applied for 5 s, ensuring close contact between the mucosal tissue and the sample. The probe was moved upward at a constant velocity (10 mm/s), and the force required to detach the mucosa from the surface of the film sample was determined as the resultant force-time plot. The analyses were performed at least in three replicate samples of each film formulation [20,27].

2.7. Water Vapor Permeability

The film samples were cut to appropriate dimensions and mounted on a glass cylindrical cell containing 10 mL of purified water. The charged cell was weighed and placed in pre-equilibrated desiccator (0% relative humidity) and maintained at temperature of 25 °C. After 24, 48, 72, 96 and 120 h, the cells were reweighed, and the water amount permeated through the film was determined from the weight loss from the assembled cell. The water vapor permeability (WVP, g/h.mm²) was calculated using the following equation [22,28,29]:

\[
WVP = \frac{m}{t \cdot A}
\]

where \( m \) is the permeated water weight (g), \( t \) is the time (h), and \( A \) the area of the film sample (mm²). All analyses were carried out at least in triplicate to estimate the inherent variability of each determination.

2.8. In Vitro Evaluation of Tramadol Release Profile

The analysis of tramadol release profile from film formulations was accomplished using a modified Franz’s cell-based apparatus, consisting of a cylindrical glass cell, and with a total capacity of 50 mL [20,30]. The temperature of analysis was 37.0 ± 0.5 °C controlled using a thermostatic bath. The dissolution medium was purified water (20 mL); the sink conditions were ensured, and constant magnetic stirring was applied. Moreover, the cellulose acetate membrane with 0.45 μm pores was used as a support (12,400 MWCO; Sigma-Aldrich, Sao Paulo, Brazil), which was allowed to stand in purified water for at least 24 h. At predetermined time intervals (15 min, 30 min, 1 h, 2 h, 4 h, and 6 h), a sample of 2.0 mL was withdrawn and the volume was replaced with purified water. The analysis was performed in at least six replicates of each film formulation. The tramadol content was determined by spectrophotometry, using a validated method [31]. Briefly, an analytical curve (calibration curve) was obtained using six replicates with dilutions of 5.0, 10.0, 35.0, 45.0, 65.0, 85.0, and 100.0 µg/mL, and was analyzed at a wavelength of \( \lambda = 271 \) nm [32].
2.9. Statistical Analysis

The physicochemical characteristics of film formulations were statistically compared using a three-way analysis of variance (ANOVA). The individual differences between means were identified using Tukey’s honestly significant difference test. Moreover, the effects of the different polymers’ amounts on swelling index, mechanical and mucoadhesive characteristics of formulations were statistically compared using DoE. Therefore, a polynomial model that correlates the independent variables and the response is further described by the following Equation (4):

\[
y = b_0 + b_1X_1 + b_2X_2 + b_3X_3 + b_{12}X_1X_2 + b_{13}X_1X_3 + b_{23}X_2X_3 + b_{123}X_1X_2X_3
\]

where \( y \) is the response, \( b_0 \) is the arithmetic mean response, \( b_1 - b_3 \) are the estimated coefficients for \( X_1 - X_3 \), respectively, and \( b_{12} - b_{23} \) are the estimated coefficients for interaction terms.

Significant differences were considered when \( p < 0.05 \), and the Statistica 10.0 software (StatSoft Company, Tulsa, OK, USA) was utilized.

3. Results and Discussion

3.1. Film Preparation

Considering the factorial design and the solvent casting method, it was possible to obtain film for all combinations of polymeric concentration. Formulations were easily removed from the molds. Initially, the macroscopic characteristics of the films were evaluated, considering flexibility, integrity, homogeneity (thin and thick parts), opacity (due to the presence of EC), and the presence of small bubbles. All these features showed varied intensities among the formulations.

They showed integrity and flexibility; however, the formulations containing the highest amount of EC (17.5%) displayed a greater amount of bubbles, as well as greater opacity, in addition to greater stiffness. These results can be found in some formulations where EC makes up more than 15% in the formulation [33]. The films containing the highest PVP concentration were more malleable and displayed greater tactile adhesiveness. These characteristics may be due to PVP’s swelling property in an aqueous medium, with the capacity to retain more than 0.5 mol of water per mol of polymer, which increased with the application of body heat [34].

3.2. Thickness and Density

The results of thickness and density of the film samples are displayed in Table 2. It was observed that the density did not show a significant statistical difference (\( p > 0.05 \)). Film formulations displayed density values from 0.00015 to 0.00021 g/mL. However, the thickness of film formulations was significantly different (\( p < 0.05 \), probably due to the different amounts of each polymer in each preparation. It was observed that the increase in the polymeric amounts increased the film thickness and mass, mainly for the formulations containing highest level of one or more polymers (e.g., F2, F4, F5, F6, F7 and F8).

Table 2. Physicochemical characteristics (thickness, mass, density, and swelling index) of film formulations composed of polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), ethylcellulose (EC) and tramadol (10%, w/w). The results represent the mean (± standard deviation) of at least three of the replicate samples analyzed.
Table 3. Mechanical and mucoadhesive properties of film formulations composed of polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), ethylcellulose (EC) and tramadol (10%, w/w). The results represent the mean (± standard deviation) of at least three of the replicate samples analyzed.

| Formulation | Young’s Modulus (MPa) | F_{max} (N) | F (N) | Folding Endurance (Times) * | Mucoadhesive Force (N) |
|-------------|-----------------------|-------------|-------|-----------------------------|-----------------------|
| F1          | 1.39 ± 0.25           | 20.19 ± 2.27| 16.97 ± 2.28| >300                        | 0.0760 ± 0.0120       |
| F2          | 2.13 ± 0.38           | 18.20 ± 1.87| 34.59 ± 2.07| >300                        | 0.1350 ± 0.0270       |
| F3          | 0.39 ± 0.02           | 15.43 ± 0.32| 13.57 ± 1.72| >300                        | 0.080 ± 0.0050        |
| F4          | 2.52 ± 0.31           | 35.51 ± 4.60| 26.32 ± 5.83| >300                        | 0.0610 ± 0.0120       |
| F5          | 4.28 ± 1.37           | 14.20 ± 4.76| 11.79 ± 5.72| >300                        | 0.0790 ± 0.0200       |
| F6          | 1.73 ± 0.22           | 13.52 ± 4.53| 8.31 ± 1.42| >300                        | 0.1330 ± 0.0150       |
| F7          | 0.61 ± 0.41           | 10.95 ± 3.11| 5.94 ± 1.09| >300                        | 0.0930 ± 0.0260       |
| F8          | 3.31 ± 0.73           | 28.80 ± 11.66| 17.90 ± 13.55| >300                        | 0.0680 ± 0.0090       |
| F9 (C)      | 4.33 ± 0.86           | 15.22 ± 8.60| 7.03 ± 1.87| >300                        | 0.0750 ± 0.0070       |
| F10 (C)     | 1.69 ± 0.28           | 20.97 ± 1.59| 7.40 ± 5.61| >300                        | 0.1000 ± 0.0050       |

F_{max} = Maximum tension; F = Fracture; * no significant statistical difference (p > 0.05).
The composition of each film formulation influenced its mechanical tensile properties (Table 3). Young’s modulus is an indicator of film stiffness, in which the higher the values, the greater the stiffness. It is defined as the ratio between the applied stress (force per unit area) and the resulting elongation (relative variation in sample length) [18]. In this study, Young’s modulus values were dependent on PVP and EC concentrations, as well as the interaction between the polymers PVA-EC and PVO-EC \((p < 0.05)\). Equation (4) was used to calculate the values of the estimate coefficients for Young’s modulus, and the resulting equation (5) is described below:

\[
y = 2.1787 + 1.0160 X_2 + 0.9020 X_3 + 1.5170 X_1 X_3 - 0.8218 X_2 X_3 + 1.1048 X_1 X_2 X_3 \quad (5)
\]

The PVA did not exert a significant influence \((p > 0.05)\), because this polymer does not provide stiffness to the film. However, as the PVP or EC amounts increased, the Young modulus of films increased \((p < 0.05)\) (Figure 1). The increased amounts of EC significantly increase the Young modulus of formulations, except when analyzing the effect of EC and PVP, where the interaction was negative. However, when the interaction among the three polymers was analyzed, the result was positive.
Figure 1. Response surface plots of mechanical tensional characteristic (Young’s modulus) of film formulations at 25 °C as a function of: (a) PVA (X₁) and PVP (X₂); (b) PVA (X₁) and EC (X₃); (c) PVP (X₂) and EC (X₃). The color scale is indicated in each figure and shows the isoparametric values.

The maximum tensile stress is indicated by the maximum point of a strain–stress curve. That is, it is the maximum tension a material can withstand when stretched before breaking. The mechanical behavior of the films can vary according to the structural characteristics of the polymers, such as molar mass, presence of polar groups, cross-links, among others. The tension is dependent on the presence of surface defects, in addition to the temperature of the test and the material [38]. Generally, the greater the number of polymers in the system, the greater the film’s mechanical strength [39]. The presence of a larger number of polymers conduces a smaller distance among the molecules that can lead to a greater interaction among the film layers and, consequently, a high resistance. In contrast, film formulations containing a smaller number of polymeric molecules can display a lesser interaction among the molecules and, consequently, a lower resistance to rupture [18,39].

In this sense, the formulations containing the lowest (F1) and highest (F8) levels of both three polymers would display the smallest and greatest values of the mechanical tensional properties, respectively. However, the highest value for Fₘₐₓ was observed for formulation F₄ (level +1 for PVA), while the lowest one was observed for F₇ (level +1 for PVA and PVP). Moreover, formulation F₂ (level +1 for EC) displayed the highest value for fracture (F = 34.59 ± 2.07 N), while F₇ displayed the lowest one (F = 5.94 ± 1.09 N).

Equation (4) was used to calculate the values of the estimate coefficients for Fₘₐₓ, and the resulting Equation (6) is described below:

\[ y = 18.4359 + 7.7514 X₁ + 10.4164 X₂ + 8.5479 X₁X₂ \] (6)

The Fₘₐₓ significantly increased as the PVA and EC amounts increased in the film formulations \((p < 0.05)\); however, the influence of PVP was not significant \((p > 0.05)\). These effects can also be observed in Figure 2.

The formulations F₄ and F₈ displayed the highest Fₘₐₓ values, 35.51 and 28.80 N, respectively. Both film formulations were composed of the highest amounts of PVA and EC polymers. In contrast, the lowest values of Fₘₐₓ were found for formulations F₇ (10.95 N), F₆ (13.52 N) and F₅ (14.20 N), which were composed of the lowest level of EC. Thus, PVA and EC are the polymers that confer resistance to the film, and it can also be inferred that there is an interaction between them. PVA and PVP have shown to result films with good mechanical properties [18,19,34]. These two polymers can interact due to the hydrogen bonds formed between the hydroxyl group of PVA and the carboxyl group of PVP [40]. The addition of small amounts of PVP to PVA results in an improvement in the stability of this polymer blend through the inter-chain bonding and also increases crystal clarity and decreases PVA degradation [41,42]. In this study, formulations F₅ to F₈ are composed of the highest amount of PVP, and it is also necessary to consider the presence of another polymer (EC). Thus, EC can compete with the PVP to make the interactions (the hydrogen bonds) with the PVA. The same behavior was observed for Young’s modulus.

The fracture or break due to the tension applied is the maximum stress that generates the sample rupture. The values for fracture were dependent on the EC concentration \((p < 0.05)\) and on the interaction between EC and PVA \((p < 0.05)\), as described by the following Equation (7):

\[ y = 12.5761 - 5.8176 X₂ + 6.6400 X₃ + 5.7130 X₁X₃ \] (7)

EC was the polymer that most influence on film strength and hardness. The concentration of PVP showed a significant effect, but this was negative. Thus, as the PVP amount increased the resistance to fracture significantly decreased \((p < 0.05)\) (Figure 3). As observed for the previous mechanical characteristics, the polymers PVA and EC resulted in films with more resistance.
Figure 2. Response surface plots of mechanical tensional characteristic ($F_{\text{max}}$) of film formulations at 25 °C as a function of: (a) PVA ($X_1$) and PVP ($X_2$); (b) PVP ($X_2$) and EC ($X_3$); (c) PVA ($X_1$) and EC ($X_3$). The color scale is indicated in each figure and shows the isoparametric values.
Figure 3. Response surface plots of mechanical tensional characteristic (Fracture) of film formulations at 25 °C as a function of: (a) PVA (X₁) and PVP (X₂); (b) PVP (X₂) and EC (X₃); (c) PVA (X₁) and EC (X₃). The color scale is indicated in each figure and shows the isoparametric values.
3.5. Mucoadhesive Properties

A pharmaceutical dosage form designed for the oral mucosa administration must be retained at the site for a suitable period of time for drug release. This time may be enough for a fast or prolonged delivery, but for the optimized drug availability. For this, the film must have an adequate mucoadhesive characteristic [11,43]. Thus, the properties of the polymer, such as the presence of specific functional groups and the flexibility of its chains, are essential for the establishment of the mucoadhesive process [14]. The results obtained for mucoadhesive force of film formulations are displayed in Table 3.

The mucoadhesive strength of the films was mainly dependent on the concentration of PVA and EC in the films \((p < 0.05)\); however, the PVA effect was negative, indicating that the increase in this polymer decreased the mucoadhesive force of formulations, as described by the following Equation (8):

\[
y = 0.0902 - 0.0304 X_1 + 0.0168 X_3 - 0.0393 X_1X_3
\]  

(8)

The increase in EC significantly increased the mucoadhesion of film formulations \((p < 0.05)\) and PVP did not show significant effect \((p > 0.05)\). Figure 4 shows the response surface plots of mucoadhesive force, indicating the main effects of each polymer.
Figure 4. Response surface plots of mucoadhesive force of film formulations as a function of: (a) PVP (X1) and EC (X3); (b) PVA (X1) and EC (X3); (c) PVA (X1) and PVP (X2). The color scale is indicated in each figure and shows the isoparametric values.

The film formulations presented similar mucoadhesive force from 0.061 to 0.135 N. The greater mucoadhesiveness were displayed by F2 (0.135 N), F6 (0.133 N) and F10 (0.100 N). The common variables between the F2 and F6 films are the low concentration of PVA and the highest EC concentration. Regarding the concentration of PVP, the formulation F2 had the smallest amount, while F6 had the largest one. The common concentration of PVA and EC in both films possibly allowed the PVP polymer to maintain its adhesiveness in the formulation, regardless of its concentration [14].

Film formulations F1, F4 and F8 displayed the lowest mucoadhesive strengths: 0.076, 0.061, and 0.068 N, respectively. The common variables between the F4 and F8 films are also the same PVA and EC amounts, both at the highest level. Due to the presence of hydroxyl groups of PVA and carboxylic groups of PVP, all formulations displayed mucoadhesive characteristics [11,14,18,20,43].

3.6. Water Vapor Permeability (WVP)

Considering the results obtained by design, the selected formulations were those containing the highest amounts of PVA, PVP and EC. However, despite the results of films with a greater amount of EC being promising, during their preparation there was difficulty in dispersing and homogenizing, generating films with a greater amount of bubbles and without uniformity. Thus, films with a higher amount of EC were not selected, and the formulations F3, F5, F7, and F9/F10 were considered for the next analysis.

The analysis of WVP allows evaluating the aqueous permeability rate of film, considering the percentage of water that passes per unit of film area and of known thickness, induced by a pressure gradient among two specific surfaces, of known relative humidity and temperature [44]. The use of insoluble materials, or materials with low solubility in water, leads to a film with low permeability within a wide range of humidity [21]. When the materials are soluble in water, the permeability rate increases, and composite films can have the advantage of bringing together the positive points of each of the materials used [20]. Permeability can be defined as a process in which vapor dissolves on one side of the film and diffuses to the other side. Factors such as morphology, density, chemical structure, crystallinity and polymeric orientation of the film can influence the water permeability rate as well as the type of solvent, plasticizer and drying rate [45].

Therefore, the WVP evaluation of film formulations enabled the determination of permeability rate in function of the different polymeric amounts of PVA, PVP and EC of selected films (Table 4).

Table 4. Water vapor permeability (WVP) as a function of time (h) of selected film formulations composed of polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), ethylcellulose (EC) and tramadol (10%, w/w).

| Formulations | WVP (× 10⁻⁹ g/h.mm²) |
|--------------|---------------------|
|              | 24 h *              | 48 h *              | 72 h *              | 96 h *              | 120 h *             |
| F3           | 1.5624 ± 0.0389     | 1.4982 ± 0.0387     | 1.4390 ± 0.0398     | 1.3919 ± 0.0349     | 1.4490 ± 0.0432     |
| F5           | 1.5481 ± 0.0435     | 1.5169 ± 0.0496     | 1.4920 ± 0.0398     | 1.4209 ± 0.0263     | 1.4710 ± 0.0489     |
| F7           | 1.7823 ± 0.0590     | 1.6190 ± 0.0280     | 1.52610 ± 0.0476    | 1.4972 ± 0.0354     | 1.6200 ± 0.0374     |
| F9 (C)       | 1.6723 ± 0.0489     | 1.5163 ± 0.0387     | 1.4910 ± 0.0452     | 1.4961± 0.0411      | 1.5900 ± 0.0399     |
| F10 (C)      | 1.6340 ± 0.0378     | 1.5129± 0.0412      | 1.4730 ± 0.0431     | 1.501± 0.0398       | 1.5410 ± 0.0452     |

* No significant statistical difference (p > 0.05).

The different concentrations of the polymers did not result in significant variations in WVP (p > 0.05). Although the results obtained are close, the formulation F7 displayed
the highest values every day, indicating that it allowed the greatest passage of water among the relaxation points of the polymeric chains. This is the film that has the highest concentrations of the PVA and PVC polymers and the lowest concentration of EC. On the other hand, the formulations F3 and F5 displayed the lowest WVP values. These, in turn, have the lowest concentrations of PVP and PVA, respectively, which suggests that decreasing the amount of these polymers decreases the relaxation of polymer chains and consequently the transmission of water through the films [19]. As these selected films have the lowest amount of EC, it is possible to improve the PVA and PVP molecules interacting [40,41].

### 3.7. In Vitro Evaluation of Tramadol Release Profile

The in vitro evaluation of tramadol release profile is a fundamental step during the development of proposed mucoadhesive fast-dissolving film system. In this context, the analysis is performed with success when the experimental conditions (sink conditions, stirring and temperature) are appropriate, simulating the in vivo conditions [21,36,46]. Tramadol hydrochloride is readily soluble in water, which was used as dissolution media to investigate the influence of the technology applied on drug release. Thus, the film formulations were analyzed with controlled temperature and agitation, and the sink conditions were maintained. The results are displayed in Figure 5.

![Figure 5](image)

**Figure 5.** The effects of different amounts of polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), and ethylcellulose (EC) on tramadol release from selected film formulations: F3, F5, F7, and F9/F10 and free tramadol. Each curve is the mean ± standard deviation of at least three analyses.

The formulation F5 and the central point (F9/F10) displayed the fastest tramadol release, and 100% of drug was released up to 15 min. Formulations F3 and F7 displayed slower release, and the total tramadol release was accomplished by 30 and 60 min, respectively.

The tramadol solution (free drug) displayed the slowest release, and it was totally released in approximately 120 min. The results obtained from the films, in comparison with the tramadol solution, showed a decrease in the drug release time; thus, we are able to infer that the polymeric platform used had an influence on the results in order to allow a faster drug release. It is noteworthy that these results were obtained in vitro and may indicate that the presence of polymers and applied technology helped in the faster dissolution of tramadol and its mass transfer to the dissolution medium through the cellulose acetate membrane.
These results are in agreement with the previous one, and indicate that the PVA, due to its characteristic of matrix formation, helps in the structuring and maintenance of the film, which allowed an increase in the drug release time. When the concentration of PVP also increased (for example, in the F7 film), this structuring became firmer, possibly due to the polymer blend formed by the hydroxyl groups of the PVA and PVP carbonyl groups [34]. It is important to emphasize that this F7 film had the lowest EC content. This composition made it possible to prolong the drug release time.

On the other hand, the concentration of EC was not taken into account, as it was at its lowest concentration in all films, except for the zero point. The F9/F10 formulations have a higher proportion of EC compared to other polymers, making the interaction between PVA and PVP difficult, as observed in the previous characterizations. Thus, at the central point, a matrix was formed that was more susceptible to the entry of the permeant (water) for the dissolution and consequent faster tramadol release. Thus, the fast tramadol release was possibly due to EC interference. The EC dispersion used (Surelease®) is an aqueous compound containing ethylcellulose, ammonium hydroxide, medium chain triglycerides and oleic acid [47], and also containing about 25% (m/m) of plasticizers, which may have contributed to the rapid release of TrHC from the formulations.

Studies have shown the solubility enhancement of poorly soluble APIs, using platforms composed of hydrophilic polymers, and electrospinning represents a useful technological strategy [48]. However, tramadol hydrochloride has a low molecular weight (299.83 g/mol) and log partition coefficient (logP) in n-octanol-water of 1.35 (at pH 7), which are advantageous characteristics from the point of mucosal absorption. Following oral administration, tramadol is rapidly and almost completely absorbed, with a bioavailability of 75% due to the first-pass metabolism (20-30%), and shows peak plasma concentrations at two hours [49,50]. Thus, the fast drug release enabled by F9/F10 formulations represents a useful means to improve the buccal absorption rate of tramadol. In addition, the effect of saliva’s flush in the buccal cavity, the swallowing of the dissolved tramadol and also the first-pass effect probably will be low.

4. Conclusions

The use of a $2^3$ factorial design, with repetition at the central point, was extremely important to help define the best polymer concentrations, to ensure a good performance during the formulation preparation steps and to identify the influence of each component in the formulation. The films were homogeneous and had high mechanical strengths and mucoadhesion. These attributes are desirable, as they contribute to the permanence of the formulation at the administration site and to greater tramadol availability. The most promising film formulations were those prepared with the greatest amount of PVA, PVP and EC. However, EC showed difficulty in dispersion and homogenization, generating films with a greater amount of bubbles and without uniformity. Thus, films with a higher amount of EC were disregarded, highlighting that films should not contain more than 15% EC. The applied technology promoted the obtainment of pharmaceutical films with adequate mechanical characteristics and mucoadhesive properties, in addition to providing fast drug release. Therefore, it was possible to develop mucoadhesive fast-dissolving films with suitable mechanical characteristics to be used as platform systems for oral administration for a faster drug action. They constitute platforms and strategies to improve the therapy of tramadol with regard to availability at the site of application, considering the necessity of rapid pain relief, and show potential for in vivo evaluation.

**Author Contributions:** Conceptualization, N.F.G.P., C.F.V. and M.L.B.; methodology, N.F.G.P., C.F.V., R.S.d.S. and M.L.B.; formal analysis, N.F.G.P., C.F.V. and R.S.d.S.; investigation, N.F.G.P. and M.L.B.; resources, N.F.G.P. and M.L.B.; data curation, N.F.G.P. and M.L.B.; writing—original draft preparation, N.F.G.P. and M.L.B.; writing—review and editing, M.L.B.; visualization, C.F.V. and R.S.d.S.; supervision, M.L.B.; project administration, M.L.B.; funding acquisition, M.L.B. All authors have read and agreed to the published version of the manuscript.
**Funding:** This research was funded by the Brazilian funding agencies CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior)/Coordination for the Improvement of Higher Education Personnel; Finance Code (001) and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico/National Counsel of Technological and Scientific Development of Brazil; Process nº 307695/2020-4).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Acknowledgments:** The authors would like to thank the support of FINEP (Financiadora de Estudos e Projetos/Financier of Studies and Projects of Brazil) and Prati-Donaduzzi for kind donation of materials.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Merskey, H. Pain terms: A list with definitions and notes on usage. Recommended by the IASP subcommittee on taxonomy. *Pain* 1979, 6, 249–252.

2. Raja, S.N.; Carr, D.B.; Cohen, M.; Finnerup, N.B.; Flor, H.; Gibson, S.; Keefe, F.J.; Mogil, J.S.; Ringkamp, M.; Sluka, K.A.; et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain* 2020, 161, 1976–1982, doi:10.1097/j.pain.0000000000001939.

3. Society, B.; Force, T. Implications of the IASP’s new definition of Pain: time for new paradigms and rescuing its meaning. *Braz. J. Pain* 2020, 3, 297–298, doi:10.9593/bjape.20180118.20200198.

4. Kim, K.-H.; Seo, H.-J.; Abdi, S.; Huh, A.B. All about pain pharmacology: what pain physicians should know. *Korean J. Pain* 2020, 33, 108–120, doi:10.3344/kjp.2020.33.2.108.

5. Bonezzi, C.; Fornasari, D.; Cricelli, C.; Magni, A.; Ventriglia, G. Not All Pain is Created Equal: Basic Definitions and Diagnostic Work-Up. *Pain Ther.* 2020, 9, 1–15, doi:10.1007/s40122-020-00217-w.

6. WHO. Tramadol Update Review: Report Agenda item 6.1. In Proceedings of the Expert Committee on Drug Dependence, Thirty-sixth Meeting, Geneva, Switzerland, 16–20 June 2014, 1–39.

7. Subedi, M.; Bajaj, S.; Kumar, M.S.; Ye, M. An overview of tramadol and its usage in pain management and future perspective. *Biomed. Pharmacother.* 2019, 111, 443–451, doi:10.1016/j.biopha.2018.12.085.

8. Eric MacLaren, A.L. Tramadol Facts, History and Statistics | Dangers and Legality. Available online: https://drugabuse.com/library/tramadol-history-and-statistics (accessed on 6 June 2021)

9. Li, X.-Q.; Ye, Z.-M.; Wang, J.-B.; Fan, C.-R.; Pan, A.-W.; Li, C.; Zhang, R.-B. Mucoadhesive buccal films of tramadol for effective pain management. *Braz. J. Anesthesiol. English Ed.* 2017, 67, 231–237, doi:10.1590/bjaene.2015.08.016.

10. Amidon, G.L.; Lennernäs, H.; Shah, V.P.; Crison, J.R. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and in Vivo Bioavailability. *Pharm. Res.* 1995, 12, 413–420, doi:10.1023/a:1016212804288.

11. Bruschi, M.L.; de Freitas, O. Oral Bioadhesive Drug Delivery Systems. *Drug Dev. Ind. Pharm.* 2005, 31, 293–310, doi:10.1081/ddc-52073.

12. Bruschi, M.L.; de Souza Ferreira, S.B.; Bassi da Silva, J. Mucoadhesive and mucus-penetrating polymers for drug delivery. In *Nanotechnology for Oral Drug Delivery—From Concept to Applications*; Martins, J.P.M., Santos, H.A., Eds.; Academic Press: London, England, 2020; pp. 77–142; ISBN 978-0-128038-9.

13. Da Silva, J.B.; Ferreira, S.B.D.S.; de Freitas, O.; Bruschi, M.L. A critical review about methodologies for the analysis of mucoadhesive properties of drug delivery systems. *Drug Dev. Ind. Pharm.* 2017, 43, 1053–1070, doi:10.1080/03639045.2017.1294600.

14. Khutoryanskiy, V.V. *Advances in Mucoadhesive Polymers and Formulations for Transmucosal Drug Delivery*; 1st ed.; MDPI: Basel, Switzerland, 2020; ISBN 978-3-0928-753-6.

15. Martins, J.P.; Santos, H.A. *Nanotechnology for Oral Drug Delivery: From Concept to Applications*; 1st ed.; Academic Press: London, England, 2020; ISBN 978-0-128038-9.

16. Bala, R.; Khanna, S.; Pawar, P.; Arora, S. Orally dissolving strips: A new approach to oral drug delivery system. *Int. J. Pharm. Invest.* 2013, 3, 67–76, doi:10.4103/2230-973x.114897.

17. Kamel, R.; Mahmoud, A.; El-Feky, G. Double-phase hydrogel for buccal delivery of tramadol. *Drug Dev. Ind. Pharm.* 2011, 38, 468–483, doi:10.3109/03639045.2011.611807.

18. Vecchi, C.F.; Cesar, G.B.; De Souza, P.R.; Caetano, W.; Bruschi, M.L. Mucoadhesive polymeric films comprising polyvinyl alcohol, polyvinylpyrrolidone, and poloxamer 407 for pharmaceutical applications. *Pharm. Dev. Technol.* 2021, 26, 138–149, doi:10.1080/10837450.2020.1849283.

19. Vecchi, C.F.; Dos Santos, R.S.; Bruschi, M.L. Technological development of mucoadhesive film containing poloxamer 407, polyvinyl alcohol and polyvinylpyrrolidone for buccal metronidazole delivery. *Ther. Deliv.* 2020, 11, 431–446, doi:10.4155/tde-2020-0031.
20. Vecchi, C.F.; dos Santos, R.S.; da Silva, J.B.; Rosseto, H.C.; Sakita, K.M.; Svizdinski, T.I.E.; Bonfim-Mendonça, P.D.S.; Bruschi, M.L. Development and in vitro evaluation of buccal mucoadhesive films for photodynamic inactivation of Candida albicans. Photodiagnosis & Photodyn. Ther. 2020, 32, 101957, doi:10.1016/j.pdpdt.2020.101957.

21. Toledo, L.D.A.S.D.; Rosseto, H.C.; Ravani, L.; Cortesi, R.; Bruschi, M.L. Waste material of propolis as a film forming agent intended to modify the metronidazole release: preparation and characterization. Curr. Drug Deliv. 2016, 13, 1152–1164, doi:10.2174/156720181366615113121827.

22. Toledo, L.D.A.S.D.; Bavato, M.I.; Rosseto, H.C.; Cortesi, R.; Bruschi, M.L. Pharmaceutical films made from the waste material from the preparation of propolis extracts: development and characterization. Braz. J. Pharm. Sci. 2015, 51, 847–859, doi:10.1590/s1984-82502015000400011.

23. Nesseem, D.I.; Eid, S.; El-Houseny, S. Development of novel transdermal self-adhesive films for tenoxican, an anti-inflammatory drug. Life Sci. 2011, 89, 430–438, doi:10.1016/j.lfs.2011.06.026.

24. Deshmank, S.V.; Channawar, M.A.; Chandewar, A.V.; Joshi, U.M.; Biyani, K.R. Chitosan based sustained release mucoadhesive buccal patches containing verapamil HCL. Int. J. Pharm. Pharm. Sci. 2009, 1, 216–229.

25. Verma, N.; Chattopadhayay, P. Preparation of Mucoadhesive Patches for Buccal Administration of Metoprolol Succinate: In Vitro and In Vivo Drug Release and Bioadhesion. Trop. J. Pharm. Res. 2012, 11, 9–17, doi:10.4314/tjpr.v11i1.2.

26. Jones, D.S.; Bruschi, M.L.; de Freitas, O.; Gremião, M.P.D.; Lara, E.H.G.; Andrews, G.P. Rheological, mechanical and mucoadhesive properties of thermoresponsive, bioadhesive binary mixtures composed of poloxamer 407 and carbopol 974P designed as platforms for implantable drug delivery systems for use in the oral cavity. Int. J. Pharm. 2009, 372, 49–58, doi:10.1016/j.ijpharm.2009.01.006.

27. Da Silva, J.B.; Ferreira, S.B.D.S.; Reis, A.; Cook, M.T.; Bruschi, M.L. Assessing Mucoadhesion in Polymer Gels: The Effect of Method Type and Instrument Variables. Polymers 2018, 10, 254, doi:10.3390/polym10030254.

28. Cao, N.; Yang, X.; Fu, Y. Effects of various plasticizers on mechanical and water vapor barrier properties of gelatin films. Food Hydrocoll. 2009, 23, 729–735, doi:10.1016/j.foodhyd.2008.07.017.

29. Kanig, J.L.; Goodman, H. Evaluative Procedures for Film-Forming Materials Used in Pharmaceutical Applications. J. Pharm. Sci. 1962, 51, 77–83, doi:10.1016/j.aps.2002.06.0115.

30. Ferreira, S.B.D.S.; Dias, B.R.D.A.; Obregón, C.S.; Gomes, C.C.; Pereira, R.R.D.A.; Godoy, J.S.R.; Svizdinski, T.I.E.; Bruschi, M.L. Microparticles containing propolis and metronidazole: in vitro characterization, release study and antimicrobial activity against periodontal pathogens. Pharm. Dev. Technol. 2014, 19, 173–180, doi:10.3109/10837450.2013.763262.

31. International Conference on Harmonization (ICH) of Technical Requirements for registration of Pharmaceuticals for Human Use, Topic Q2 (R1): Validation of Analytical Procedures: Text and Methodology, Geneva, 2005, 1–13.

32. Küçük, A.; Kalsoğlu, Y. Determination of tramadol hydrochloride in ampoule dosage forms by using UV spectrophotometric and HPLC-DAD methods in methanol and water media. Il Farm. 2005, 60, 163–169, doi:10.1016/j.farmac.2004.12.002.

33. Colorcon. Surelease – Aqueous Ethylcellulose Dispersion: Application Data. Available online: https://www.colorcon.com/products-formulation/all-products/download/322/563/34?method=view (accessed on 6 June 2021).

34. Abdelrazek, E.; Elshamawi, I.; Labeeb, S. Chitosan filler effects on the experimental characterization, spectroscopic investigation and thermal studies of PVA/PVP blend films. Phys. B Condens. Matter 2010, 405, 2021–2027, doi:10.1016/j.physb.2010.01.095.

35. Ammar, H.O.; Ghorab, M.M.; Mahmoud, A.A.; Shalal, H.I. Design and in vitro/in vivo evaluation of ultra-thin mucoadhesive buccal film containing fluticasone propionate. AAPS PharmSciTech. 2016, 18(1), 93–103, doi:10.1208/s12249-016-0496-0.

36. Nova, M.V.; Gonçalves, M.D.C.P.; Nogueira, A.C.; Herculano, L.D.S.; Medina, A.N.; Bazotte, R.B.; Bruschi, M.L. Formulation and characterization of ethylcellulose microparticles containing 1-alamyl-1-glutamine peptide. Drug Dev. Ind. Pharm. 2013, 40, 1308–1317, doi:10.3109/03639045.2013.817417.

37. Rosseto, H.C.; Toledo, L.D.A.S.D.; dos Santos, R.S.; de Francisco, L.M.B.; Vecchi, C.F.; Esposito, E.; Cortesi, R.; Bruschi, M.L. Design of propolis-loaded film forming systems for topical administration: The effect of acrylic acid derivative polymers. J. Mol. Liq. 2021, 322, 114514, doi:10.1016/j.molliq.2020.114514.

38. Black, J.T.; Kohser, R.A. DeGarmo’s Materials and Processes in Manufacturing, 13th ed.; John Wiley & Sons: Hoboken, NJ, USA, 2019; ISBN 1119723299.

39. Moreno, M. Application of small punch testing on the mechanical and microstructural characterizations of P91 steel at room temperature. Int. J. Press. Vessel. Pip. 2016, 142–143, 1–9, doi:10.1016/j.jipvpp.2016.04.002.

40. Teodorescu, M.; Berciu, M.; Morariu, S. Biomaterials of PVA and PVP in medical and pharmaceutical applications: Perspectives and challenges. Biotechnol. Adv. 2019, 37, 109–131, doi:10.1016/j.biotechadv.2018.11.008.

41. Kana, Y.; Milner, P.; Dini, D.; Amis, A.A. Tribological properties of PVA/PVP blend hydrogels against articular cartilage. J. Mech. Behav. Biomed. Mater. 2018, 78, 36–45, doi:10.1016/j.jmbbm.2017.10.027.

42. Thomas, J.; Lowman, A.; Marcolongo, M. Novel associated hydrogels for nucleus pulposus replacement. J. Biomed. Mater. Res. Part A 2003, 67, 1329–1337, doi:10.1002/jbr.a.10119.

43. Carvalho, F.C.; Bruschi, M.L.; Evangelista, R.C.; Gremião, M.P.D. Mucoadhesive drug delivery systems. Braz. J. Pharm. Sci. 2010, 46, 1–17, doi:10.1590/s1984-82502010000100002.

44. Toledo, L.D.A.S.D.; Rosseto, H.C.; Bruschi, M.L. Iron oxide magnetic nanoparticles as antimicrobials for therapeutics. Pharm. Dev. Technol. 2017, 23, 316–323, doi:10.1080/10837450.2017.1337793.

45. ASTM - American Society for Testing & Materials. Designation D882-12: Standard test method for tensile properties of thin plastic sheeting. Annual Book of ASTM Standards;ASTM: Philadelphia, USA, 2012.
46. Florence, A.T.; Attwood, D. Physicochemical Principles of Pharmacy, 5th ed.; Pharmaceutical Press: London, UK, 2011; ISBN 9780853699842.

47. DeMerlis, C.; Schoneker, D.; Borzelleca, J. A subchronic toxicity study in rats and genotoxicity tests with an aqueous ethylcellulose dispersion. Food Chem. Toxicol. 2005, 43, 1355–1364, doi:10.1016/j.fct.2005.03.008.

48. Szabó, P.; Daróczi, T.B.; Tóth, G.; Zelkó, R. In vitro and in silico investigation of electrospun terbinafine hydrochloride-loaded buccal nanofibrous sheets. J. Pharm. Biomed. Anal. 2016, 131, 156–159, doi:10.1016/j.jpba.2016.08.021.

49. Drugbank Online. Tramadol. Available online: https://go.drugbank.com/drugs/DB00193. (accessed on 6 June 2021).

50. Auro Pharma Inc. Product monograph including patient medication information: Auro-Tramadol. Available online: http://www.auropharma.ca/products/monograph/Auro-Tramadol%20PM%20-%20english.pdf. (accessed on 6 June 2021).